权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Commercializing the μSIM: A Modular Platform for the Development and Analysis of Barrier Tissue Models

商业化μSIM：用于屏障组织模型开发和分析的模块化平台

基本信息

批准号：
10580031
负责人：
James Andrew Roussie
金额：
$ 80.08万
依托单位：
SIMPORE, INC.
依托单位国家：
美国
项目类别：
财政年份：
2020
资助国家：
美国
起止时间：
2020-05-06 至 2025-02-28
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10580031
关键词：
Address Agreement Apical Architecture Automation Biological Phenomena Blood Vessels Cell Culture Techniques Cells Coculture Techniques Collaborations Development Devices Disease Drug Formulations Electrical Resistance Feedback Foundations Future Glues Goals Image Immune In Vitro Injections Journals Laboratories Laboratory Research Lung Manufacturer Marketing Membrane Microfluidics Microscopy Molds Molecular Names Nanoporous Optics Permeability Pharmaceutical Preparations Phase Play Polymers Porosity Positioning Attribute Price Process Production Property Publications Reporting Research Resolution Sales Science Silicon Small Business Innovation Research Grant Specific qualifier value Technology Thick Tissue Microarray Tissue Model Tissues Translating Universities absorption commercialization cost design fabrication field study fluid flow improved in vitro Model light scattering live cell imaging live cell microscopy manufacture manufacturing capabilities manufacturing test membrane assembly meter microphysiology system monolayer nanomembrane professor prototype response success three dimensional cell culture tool trafficking

项目摘要

Abstract This project will commercialize a cell culture platform featuring SiMPore's ultrathin silicon- based membrane technology to enable advanced research on tissue barriers. In vitro models of tissue barriers such as the gut, lung, and vasculature are important for understanding the basis of disease and for assessing the ability of drug formulations to reach target tissues. Despite the growing use of sophisticated cell culture platforms (e.g., 3D cell culture, microphysiological systems, and tissue chips), the simplest and most popular tools for the in vitro study of barrier tissues remains the Corning Transwell™ and its competitors (collectively referred to herein as “Transwells™”). These products have a suspended ~ 10 µm thick polymer membrane creating apical and basal compartments which separate mono- or co-cultures grown on the membranes. Despite their popularity, Transwells® do not support high resolution microscopy nor provide the ﬂuid ﬂow needed to properly study vascular barriers and immune cell traﬃcking. SiMPore's membranes will be commercialized as cell culture products that overcome limitations of Transwells®, while retaining their easy to use format and oﬀering features found in more sophisticated tissue chips. Our Phase I project successfully translated the laborious hand-made devices used in the laboratory of Professor James McGrath (University of Rochester) to a scalable fabrication workﬂow at SiMPore. Using a modular design, we developed an open-well Transwell-style culture unit that incorporates SiMPore's membranes, which further converts to a ﬂow cell with the addition of a plug-and-play ﬂow module. Devices were distributed to nine collaborating laboratories, all of whom reported success with the platform. SiMPore also successfully translated the dual-scale micro/nanoporous membranes developed by the McGrath laboratory to wafer-scale manufacturing. Our Phase II project will create commercially viable versions of Phase I prototypes to be marketed under the CytoVu™ brand. Aim 1 will increase membrane manufacturing capacity by relieving production bottlenecks and integrating automation. Aim 2 focuses on automating CytoVu™ device assembly. Aim 3 will test the manufactured devices in a network of collaborating laboratories while developing accessories that make the platform increasingly versatile and easy to use. This project will establish scalable manufacturing capacity at SiMPore for the CytoVu™ and its accessories, and also validate CytoVu™ products as competitive alternatives to incumbent products for the in vitro study of barrier tissues.

摘要